Skip to content
WorldBrand.AI

Zhongxin Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2019

    Fined for Selling Substandard Medicine; Suxiao Jiuxin Pill Faces Overpromotion Concerns

    Zhongxin Pharmaceutical was penalized by Tianjin regulators for selling Pu Huang that failed microscopic identification and was deemed a substandard drug. Its major product Suxiao Jiuxin Pill was questioned over exaggerated promotion, and in 2021 the National Medical Products Administration required label revisions to add contraindications and adverse reactions. Illegal gains were confiscated and the label was revised.

    Source